Dagny Ståhlberg, Eva Reihnér, Mats Rudling, Lars Berglund, Kurt Einarsson, Bo Angelin – 1 April 1995 – Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal‐weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls.

Koichi Tsuneyama, Judy van de Water, Patrick S. C. Leung, Sanghoon Cha, Yasuni Nakanuma, Marshall Kaplan, Ronald de Lellis, Ross Coppel, Aftab Ansari, M. Eric Gershwin – 1 April 1995 – Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease characterized histologically by non‐suppurative destructive cholangitis. Sera from patients with PBC react with a series of intramitochondrial enzymes with the immunodominant response directed against the E2 component of the pyruvate dehydrogenase complex (PDC‐E2).

John Devlin, Julia Wendon, Nigel Heaton, Kai‐Chah Tan, Roger Williams – 1 April 1995 – Emergency transplantation for acute liver failure has a significantly inferior outcome than transplantations performed for elective indications. The severity of the pretransplantation clinical illness in this group will contribute to the reduced patient survival.

François Durand, Jacques Bernuau, Dominique Pessayre, Didier Samuel, Jacques Belaiche, Claude Degott, Henri Bismuth, Jacques Belghiti, Serge Erlinger, Bernard Rueff, Jean Pierre Benhamou – 1 April 1995 – Isoniazid and pyrazinamide are well‐known hepatotoxic drugs, often used in combination. The aim of this study was to assess the prognostic influence of pyrazinamide on the outcome of fulminant or subfulminant liver failure caused by antituberculous therapy. Eighteen patients with fulminant or subfulminant liver failure due to antituberculous therapy were studied.

James A. Underhill, Peter T. Donaldson, Derek G. Doherty, Koji Manabe, Roger Williams – 1 April 1995 – In recent years there has been an increasing interest in the link between susceptibility to autoimmune liver disease and genes of the HLA system, although the role of the DPB1 locus in British patients has only been investigated in autoimmune hepatitis.

Sun‐Lung Tsai, Yun‐Fan Liaw, Chau‐Ting Yeh, Chia‐Ming Chu, George C. Kuo – 1 April 1995 – Several lines of evidence have suggested that immune mechanisms are involved in the pathogenesis of hepatitis B virus (HBV)— and hepatitis C virus (HCV)‐related hepatitis. Study of patients with dual HBV and HCV infection raises the question of which is etiologically more relevant in determining the liver cell damage.

Ke‐Qin Hu, Chang‐Hong Yu, Sunny Lee, Federico G. Villamil, John M. Vierling – 1 April 1995 – Hepatitis C virus (HCV) RNA polymerase chain reaction (PCR) is widely used for diagnosis of HCV infection and evaluation of therapy. The sensitive hepatitis B virus (HBV) DNA PCR is often reserved for detection of quantities of HBV DNA that are insufficient for hybridization. Application of both PCR techniques is limited by their labor‐intensity, potential for contamination, and substantial time required for analysis.

Monique E. De Paepe, Bart Keymeulen, Daniel Pipeleers, Günter Klöppel – 1 April 1995 – The liver offers an adequate site for the metabolic function of pancreatic islet implants. Little is known about the effects of the islet grafts on the host organ. This study examines liver tissue of normal or streptozotocin (STZ)‐diabetic rats at different intervals following intraportal injection of syngeneic islets. Implantation of 800‐islet—grafts, containing 0.9 million beta cells, normalized overt diabetes within 14 days.

Koichi Kozaki, Hiroto Egawa, Luiz Bermudez, Emmet B. Keefe, Samuel K. So, Carlos O. Esquivel – 1 April 1995 – Previous research with pentoxifylline (PTX), a methylxanthine phosphodiesterase inhibitor, suggests that this drug may be capable of suppressing the activation of Kupffer cells and thereby help decrease liver injury after transplantation. To investigate this possibility, the current study sought to determine whether the release of O2− and tumor necrosis factor (TNF) from Kupffer cells in donor livers can be suppressed if the organs are exposed to PTX before preservation.

Erwin Regoeczi, Paul A. Chindemi – 1 April 1995 – Five different forms of transferrin (rat apo [iron‐free], rat diferric, diferric rat asialo, human diferric, and diferric human asialotransferrin type 3) were used to monitor the passage of this protein and its metal to the bile. Cumulative biliary excretion of the dose over 3 hours was determined. In addition, an excretion profile was constructed from the concentration of tracer in bile samples collected over 10‐minute intervals.